Focal segmental glomerulosclerosis: A Patient Guide
At a Glance
Focal segmental glomerulosclerosis (FSGS) is a pattern of scarring in the kidney’s filters that can cause protein to leak into urine. The cause—primary, secondary, genetic, or undetermined—guides treatment, with remission and kidney protection as key goals.
Focal Segmental Glomerulosclerosis (FSGS) is a term that describes a specific pattern of scarring within the kidney’s filtering units, known as glomeruli [1]. It is not a single disease with a single cause, but rather a “final common pathway” of injury that can be triggered by many different factors [2]. When these filters become scarred, they lose their ability to keep vital proteins in your blood, causing them to leak into your urine. This process, if left unmanaged, can lead to a cycle of further injury and declining kidney function [3].
To provide effective care, the medical community categorizes FSGS into four main groups based on the underlying cause. Primary FSGS is typically a clinical-pathologic diagnosis made when nephrotic syndrome is present without an identifiable secondary cause, often proposed to involve an unidentified factor in the blood that affects the filters. Secondary FSGS occurs when the kidney is stressed or overworked by other conditions, such as high blood pressure, obesity, or certain viral infections. Genetic FSGS stems from inherited changes in the DNA that affect the kidney’s structure, while FSGS of Undetermined Cause is used when the specific trigger remains unclear despite testing or when severe nephrotic syndrome is absent [2][4].
Because the causes are so different, the approach to treatment must be precisely tailored to the individual. Primary FSGS with nephrotic syndrome is often treated with medications that suppress the immune system. In contrast, secondary and genetic forms generally do not receive these strong drugs; instead, management focuses on “supportive care,” such as blood pressure control, weight management, and medications that reduce the pressure inside the kidneys to preserve their long-term health [4][5].
The ultimate goal of any treatment plan is to achieve remission, which means significantly reducing the amount of protein leaking into the urine. Reaching complete or partial remission lowers the risk of future kidney failure and is a major treatment goal. By working closely with a specialized care team to identify the root cause of your injury and consistently monitoring your protein levels and kidney function (eGFR), you can take an active role in protecting your overall well-being [6][7].
In this guide
6 chapters
Building a Clear Picture of Your FSGS Diagnosis
Learn what an FSGS diagnosis means, how primary, secondary, genetic, and undetermined types differ, and how biopsy findings guide personalized kidney care.
The Biology and Pathology of FSGS
Learn how focal segmental glomerulosclerosis (FSGS) injures podocytes, why biopsies can miss scars, and what its four causes and five Columbia variants mean.
Recognizing Symptoms and Managing Red Flags
Learn to recognize FSGS symptoms, nephrotic syndrome warning signs, and emergencies involving blood clots, infection, kidney injury, or very high blood pressure.
Navigating Your Treatment Options for FSGS
Learn how FSGS treatment depends on its cause, including steroids, calcineurin inhibitors, blood pressure medicines, SGLT2 inhibitors, and supportive care.
Monitoring Your Health and Looking Forward
Learn how remission and daily monitoring affect focal segmental glomerulosclerosis prognosis, eGFR, blood pressure, and transplant recurrence risk over time.
Building Your Care Team and Seeking Specialized Testing
Learn how focal segmental glomerulosclerosis (FSGS) care teams, biopsy review, genetic testing, transplant planning, and trials can guide treatment decisions.
Common questions in this guide
What are the main types of FSGS?
What does a diagnosis of primary FSGS mean?
Will I need immune-suppressing medicine for FSGS?
What does remission mean in FSGS?
How can I help protect my kidneys with FSGS?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Focal segmental glomerulosclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my biopsy and symptoms, which of the four main categories of FSGS do you suspect I have?
- 2.How will we determine if my FSGS is 'primary' and requires immune-suppressing medication, or 'secondary' and requires a different approach?
- 3.What is our target for my protein levels, and how often will we monitor my urine to see if we are reaching remission?
- 4.Are there specific lifestyle changes, such as sodium restriction or weight management, that are most critical for my specific situation?
References
References (7)
- 1
Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.
Shabaka A, Tato Ribera A, Fernández-Juárez G
Nephron 2020; (144(9)):413-427 doi:10.1159/000508099.
PMID: 32721952 - 2
Indications for genetic testing in adults with focal segmental glomerulosclerosis.
Pilco-Terán M, Shabaka A, Furlano M, et al.
Nefrologia 2025; (45(2)):135-149 doi:10.1016/j.nefroe.2025.02.001.
PMID: 39952830 - 3
Focal Segmental Glomerulosclerosis.
Rosenberg AZ, Kopp JB
Clinical journal of the American Society of Nephrology : CJASN 2017; (12(3)):502-517 doi:10.2215/CJN.05960616.
PMID: 28242845 - 4
Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.
Mirioglu S, Daniel-Fischer L, Berke I, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(4)):569-580 doi:10.1093/ndt/gfae025.
PMID: 38341276 - 5
Podocytopathies.
Kopp JB, Anders HJ, Susztak K, et al.
Nature reviews. Disease primers 2020; (6(1)):68 doi:10.1038/s41572-020-0196-7.
PMID: 32792490 - 6
Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.
Greenwood AM, Gunnarsson R, Neuen BL, et al.
Nephrology (Carlton, Vic.) 2017; (22(7)):520-530 doi:10.1111/nep.12816.
PMID: 27170059 - 7
Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost JP, Trachtman H, Spino C, et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (77(2)):216-225 doi:10.1053/j.ajkd.2020.04.014.
PMID: 32791086
This FSGS guide is for informational purposes only and does not constitute medical advice. Your nephrology team can interpret your biopsy, protein levels, kidney function, and treatment options.